When the right molecule meets the right mechanism, energy can return. Image posed by a model, not the patient described in this article. Photo: Brooke Cagle on Unsplash.
By Dr Jean-Marc Sobczyk, MD, GMC 6148690. Reviewed 30 October 2026.
A case: fourteen supplements and still getting worse
A woman in her late thirties came to see me after years of fatigue, anxiety and insomnia, despite working with several practitioners. Her blood tests showed borderline low B12, raised homocysteine and persistently raised inflammatory markers. Her protocol looked impressive on paper: methylfolate, methylcobalamin (methyl B12), magnesium, zinc, NAC, B6, CoQ10 and more. Yet she felt worse.
We changed one molecule, and the picture shifted. This article explains why.
Clinical takeaway: when a complex protocol fails, look for the biochemical roadblock. A single targeted change can matter more than adding another supplement.
"Methyl B12 intolerance" is a description, not a mechanism
Many patients are told they are "intolerant" of methyl B12 and the supplement is simply stopped. That label describes a reaction; it does not explain it. The more useful clinical question is: which pathway is misfiring? In my practice I use a three-way framework. The three patterns can look similar, but the history and basic blood tests help separate them, and they need different responses.
1. Overmethylation
Typically flushing, headaches and worse anxiety soon after dosing, often when high-dose methylcobalamin and high-dose methylfolate are combined. A commonly proposed contributor is slower catecholamine clearance (for example, COMT variants), although this is a clinical model rather than an established diagnosis. Approach: reduce methyl donors and review the whole protocol.
2. Methyl trapping
When B12 is insufficient, methionine synthase (MTR) cannot use 5-methyltetrahydrofolate, so folate becomes "trapped" in its methylated form. Homocysteine rises despite supplementation, and more methylfolate does not help. This is the classic "methyl-folate trap" described in B12 deficiency. Approach: secure B12 status before increasing folate.
3. Oxidative stalling of the MTR/MTRR system
This was my patient's pattern. In my clinical experience it is common among chronically unwell patients who have not responded to standard methylation protocols. That is a clinical impression from my practice, not a measured prevalence; good epidemiological data do not yet exist.
The mechanism
MTR recycles homocysteine back to methionine. To work, its cobalamin cofactor must be in the reduced cob(I)alamin state. That state is fragile: during normal turnover it is periodically oxidised to the inactive cob(II)alamin form. Methionine synthase reductase (MTRR) uses electrons from NADPH to reactivate it, together with S-adenosylmethionine (1).
In patients with a high inflammatory or oxidative burden (chronic infection, mould exposure, toxic metals or unresolved gut dysfunction), nitric oxide and superoxide are raised and can combine to form peroxynitrite, a highly reactive oxidant (3). The working hypothesis is that this environment oxidises the cobalamin centre of MTR faster than MTRR can reactivate it, so the enzyme stalls. Cell studies also suggest the relationship runs both ways: impaired MTRR function is associated with increased oxidative stress (2), which can create a self-reinforcing loop.
This is neither overmethylation nor methyl trapping. Think of it as a seized engine: adding more fuel does not help. More methylcobalamin cannot push the cycle forward if the enzyme it feeds is not available.
How I recognise the pattern
- Symptoms: persistent fatigue, worsening brain fog, and anxiety or insomnia that worsen after methyl donors are introduced, despite an otherwise comprehensive protocol.
- Blood tests: homocysteine that does not fall with methylation support, persistently raised inflammatory markers (such as CRP) or oxidative stress markers, and borderline B12 with clinical features of deficiency.
- Clinical pattern: early tolerance of methylfolate, then worsening once methylcobalamin is added, or improvement with hydroxocobalamin when methylcobalamin made things worse.
The switch: methylcobalamin to hydroxocobalamin
Hydroxocobalamin is a natural form of B12 that binds nitric oxide, a property that has been proposed as one reason it may help in states of nitrosative stress (3). The body can convert it into both active coenzyme forms, methylcobalamin and adenosylcobalamin, at the pace its own biochemistry allows.
In practice, the form, dose, route (oral or injection) and frequency are individualised and adjusted to response and tolerance, with slow titration in people with a high oxidative burden. This should be done with a clinician who can review your blood results; please do not change prescribed treatment on the basis of this article.
Hydroxocobalamin is not a lesser form of B12. For a system under oxidative strain, it can be a better entry point.
What happened next
We did not overhaul her protocol. Within weeks her sleep improved from around four hours a night to almost six, her homocysteine fell by 18 per cent and her CRP came down. Same diagnosis, same MTHFR variant, one molecule changed. This is a single case and does not prove the approach works for everyone, but it illustrates why the mechanism matters.
Clinical pearl: before stopping methyl B12 or increasing the dose, ask why the patient is reacting to it.
References
- Olteanu H, Banerjee R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J Biol Chem. 2001;276(38):35558-63. PMID: 11466310. [Established: biochemistry]
- Richard E, et al. J Cell Biochem. 2013;114. MTRR deficiency, oxidative stress and apoptosis in patient fibroblasts. PMID: 23192916. [Emerging: cell studies]
- Pall ML. Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger. J Chronic Fatigue Syndr. 2001;8(2):39-44. doi:10.1300/J092v08n02_04. [Hypothesis paper]
More on MTHFR and methylation: join the Methylation Hub on Skool or book a consultation.
This page is general information and does not replace personal medical advice. The case is shared with the patient's consent, with identifying details kept to a minimum. Dr Jean-Marc Sobczyk, GMC 6148690.